Activation of these receptors by means of GnRH agonists was shown to significantly decrease the proliferation and the motility of melanoma cell lines and the tumor growth inhibitory effect of a drug-containing GnRH conjugate (AN-207) clearly indicated that GnRH-R receptors are suitable for targeted tumor therapy [24,26]. Here, GNRH1 is linked to melanoma.